Tranquility Partners LLC Sells 1,469 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Tranquility Partners LLC decreased its position in IQVIA Holdings Inc. (NYSE:IQV) by 8.1% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 16,628 shares of the medical research company’s stock after selling 1,469 shares during the quarter. IQVIA accounts for about 1.6% of Tranquility Partners LLC’s investment portfolio, making the stock its 12th biggest holding. Tranquility Partners LLC’s holdings in IQVIA were worth $3,847,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. International Assets Investment Management LLC bought a new stake in shares of IQVIA in the 4th quarter valued at approximately $13,759,000. Kentucky Retirement Systems bought a new stake in shares of IQVIA in the 3rd quarter valued at approximately $2,994,000. Schwartz Investment Counsel Inc. boosted its position in IQVIA by 4.1% during the fourth quarter. Schwartz Investment Counsel Inc. now owns 178,690 shares of the medical research company’s stock worth $41,345,000 after purchasing an additional 7,050 shares during the period. Dfpg Investments LLC bought a new stake in IQVIA during the fourth quarter worth approximately $1,106,000. Finally, Sei Investments Co. boosted its position in IQVIA by 20.2% during the third quarter. Sei Investments Co. now owns 94,748 shares of the medical research company’s stock worth $18,641,000 after purchasing an additional 15,913 shares during the period. Institutional investors own 89.62% of the company’s stock.

IQVIA Stock Performance

Shares of NYSE IQV traded down $1.88 during trading hours on Wednesday, reaching $227.26. The stock had a trading volume of 705,876 shares, compared to its average volume of 973,666. The business’s fifty day moving average is $244.16 and its two-hundred day moving average is $221.33. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.86 and a quick ratio of 0.86. The company has a market cap of $41.25 billion, a price-to-earnings ratio of 31.43, a PEG ratio of 2.24 and a beta of 1.50. IQVIA Holdings Inc. has a twelve month low of $167.42 and a twelve month high of $261.73.

IQVIA (NYSE:IQV) last issued its earnings results on Wednesday, February 14th. The medical research company reported $2.84 EPS for the quarter, beating analysts’ consensus estimates of $2.82 by $0.02. The business had revenue of $3.87 billion during the quarter, compared to analyst estimates of $3.80 billion. IQVIA had a return on equity of 29.32% and a net margin of 9.06%. IQVIA’s revenue was up 3.5% on a year-over-year basis. During the same period in the prior year, the company posted $2.54 earnings per share. As a group, research analysts expect that IQVIA Holdings Inc. will post 10.11 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. Leerink Partnrs reaffirmed an “outperform” rating on shares of IQVIA in a research report on Monday, February 26th. Barclays upped their target price on IQVIA from $260.00 to $265.00 and gave the stock an “overweight” rating in a research report on Thursday, February 15th. StockNews.com raised IQVIA from a “hold” rating to a “buy” rating in a research report on Friday, February 16th. BTIG Research assumed coverage on IQVIA in a research report on Tuesday, February 13th. They set a “buy” rating and a $285.00 target price for the company. Finally, Guggenheim lowered IQVIA from a “buy” rating to a “neutral” rating in a report on Thursday, February 15th. Three analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $256.80.

Insiders Place Their Bets

In other IQVIA news, insider Kevin C. Knightly sold 8,607 shares of the stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $250.17, for a total transaction of $2,153,213.19. Following the completion of the transaction, the insider now directly owns 5,251 shares in the company, valued at $1,313,642.67. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other IQVIA news, insider Eric Sherbet sold 1,000 shares of the stock in a transaction on Friday, February 16th. The stock was sold at an average price of $241.50, for a total transaction of $241,500.00. Following the completion of the transaction, the insider now directly owns 20,836 shares in the company, valued at $5,031,894. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Kevin C. Knightly sold 8,607 shares of the stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $250.17, for a total value of $2,153,213.19. Following the transaction, the insider now owns 5,251 shares of the company’s stock, valued at $1,313,642.67. The disclosure for this sale can be found here. Insiders sold 41,285 shares of company stock worth $10,331,003 over the last three months. 1.60% of the stock is currently owned by corporate insiders.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.